Claims for Patent: 9,474,731

Summary for Patent: 9,474,731

Title:	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Abstract:	This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US15/182,253
Patent Claims:	1. A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in a Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 20 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 2. The method of claim 1, wherein dextromethorphan is orally co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 3. The method of claim 2, wherein dextromethorphan is orally co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion in a single dosage form. 4. The method of claim 3, wherein the oral dosage form is solid. 5. The method of claim 4, wherein the solid, oral dosage form is a tablet, a troche, a pill, or a capsule. 6. The method of claim 1, wherein dextromethorphan is co-administered once a day with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 7. The method of claim 1, wherein dextromethorphan is co-administered twice a day with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 8. The method of claim 7, wherein about 40 mg to about 100 mg of dextromethorphan is administered. 9. The method of claim 1, wherein about 50 mg to about 150 mg of bupropion is administered. 10. The method of claim 9, wherein bupropion is administered twice a day. 11. The method of claim 1, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for at least 14 days. 12. The method of claim 1, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for at least 30 days. 13. The method of claim 1, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for at least 60 days. 14. The method of claim 1, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for at least 90 days. 15. The method of claim 11, wherein on the tenth day of co-administration, the Cmin of dextromethorphan is at least 30 times the Cmin of dextromethorphan that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, for ten consecutive days. 16. A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in an Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 30 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 17. The method of claim 16, wherein dextromethorphan is co-administered with bupropion or hydroxybupropion. 18. The method of claim 16, wherein dextromethorphan is co-administered with bupropion or erythrohydroxybupropion. 19. The method of claim 16, wherein dextromethorphan is co-administered with bupropion or threohydroxybupropion. 20. The method of claim 16, wherein the bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or dextromethorphan is deuterium-modified. 21. The method of claim 20, wherein the dextromethorphan is deuterium-modified. 22. A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering dextromethorphan with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, once or twice a day for at least eight consecutive days, wherein bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion is administered in an amount that results in an Cmin of dextromethorphan in the human being, on the eighth day, that is at least about 40 ng/mL and is at least 30 times the Cmin that would have been achieved by administering the same amount of dextromethorphan without bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for eight consecutive days, and wherein dextromethorphan is present in the body of the human being at the same time as bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion. 23. The method of claim 22, wherein on the eighth day of co-administration, the Cmin of dextromethorphan is at least 50 ng/mL. 24. The method of claim 22, wherein on the eighth day of co-administration, the Cmin of dextromethorphan is at least 60 ng/mL. 25. The method of claim 24, wherein on the eighth day of co-administration, the Cmax of dextromethorphan is at least 80 ng/mL. 26. The method of claim 22, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion for at least 14 days. 27. The method of claim 22, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, for at least 30 days. 28. The method of claim 22, wherein dextromethorphan is co-administered with bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, for at least 60 days. 29. The method of claim 22, wherein about 40 mg to about 50 mg of dextromethorphan are administered per dose.